Bromday®
Bromfenac 0.09% · ophthalmic solution
NSAID
Approved uses
Postoperative inflammation and ocular pain after cataract surgery
One drop QD to the affected eye(s) starting 1 day before surgery, on the day of surgery, and through the first 14 days postoperatively.
Pain-free rates beat placebo from day 1, with inflammation cleared by day 15.
OFF-LABELNot in the FDA label for this product
Cystoid macular edema prophylaxis after cataract surgery
Bromfenac 0.09% one drop BID for 2 weeks, alone or with dexamethasone 0.1% QID tapering by one drop per day each following week.
RCT · n=914 · combo only
ESCRS PREMED, a randomized multicenter trial in 914 nondiabetic patients, compared 0.09% BID, dexamethasone 0.1%, and the two combined. Clinically significant macular edema within 12 weeks occurred in 3.6% with the NSAID alone, 5.1% with the steroid alone, and 1.5% with the combination (overall P = .043), and the authors concluded that the combination, not either drug alone, lowered the risk.
Ocular pain and discomfort after photorefractive keratectomy
Bromfenac 0.09% one drop BID postoperatively, applied after a bandage contact lens was fitted; the report states no total duration.
Open-label RCT · n=212 eyes
Open-label randomized trial in 212 eyes found no significant difference between 0.09% BID and ketorolac 0.4% QID in postoperative pain, burning, foreign body sensation, or photophobia, and no difference in epithelial healing rates. A smaller double-masked randomized trial (29 patients, 58 eyes) dosing every agent TID found slower mean reepithelialization on bromfenac 0.09%, 7.25 days versus 5.50 days for nepafenac 0.1% and 5.62 days for ketorolac 0.4% (P < .05).
Contraindications
None listed on the FDA label.
0.09% ophthalmic solution, 1.7 mL dropper bottle
Nonsteroidal anti-inflammatory drug with anti-inflammatory activity; its mechanism of action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation, and in animal eyes they have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
Warnings & Precautions
- Keratitis and corneal reactions: Topical NSAIDs may cause keratitis, and continued use in susceptible patients may progress to epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation, any of which may be sight threatening. Discontinue immediately on evidence of corneal epithelial breakdown and monitor corneal health closely.
- Corneal adverse events: Post-marketing experience suggests patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases such as dry eye, rheumatoid arthritis, or repeat ocular surgeries within a short period may be at increased risk for corneal adverse events, which may become sight threatening; use with caution in these patients. Use more than 24 hours before or beyond 14 days after surgery may increase their occurrence and severity.
- Sulfite allergic reactions: Contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people; sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.
- Delayed healing: All topical NSAIDs may slow or delay healing, topical corticosteroids are also known to slow or delay healing, and concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
- Cross-sensitivity: Potential cross-reactivity with acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs; use caution in patients who have reacted to these drugs.
- Increased bleeding time: With some NSAIDs, there is a potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues, including hyphemas, in conjunction with ocular surgery. Use caution with known bleeding tendencies or drugs that may prolong bleeding time.
- Contact lens wear: Not to be administered while wearing contact lenses.
Common Side Effects
The most commonly reported adverse experiences after cataract surgery were abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning and stinging), eye pain, eye pruritus, eye redness, headache, and iritis, reported in 2 to 7% of patients. Post-marketing reports include corneal erosion, corneal perforation, corneal thinning, and epithelial breakdown, and estimates of their frequency cannot be made.
Pregnancy: No adequate and well-controlled studies in pregnant women (Pregnancy Category C on this label); use during pregnancy only if the potential benefit justifies the potential risk to the fetus, and avoid during late pregnancy because prostaglandin synthesis inhibitors can close the fetal ductus arteriosus. Oral dosing in rats and rabbits showed no teratogenicity, but produced embryo-fetal lethality, increased neonatal mortality, and reduced postnatal growth in rats and increased post-implantation loss in rabbits.
Lactation: Exercise caution when administering to a nursing woman.
Safety and efficacy below age 18 not established.